Bedaquiline, a 'miracle drug' for multi-drug resistant tuberculosis and extensively-drug resistant TB will be available from Monday at select public hospitals in India.

According to a leading daily, the treatment has been rolled out under the Revised National Tuberculosis Control Programme and is part of co-ordinated programme between the government and Johnson & Johnson.

Initially, the drug will be available in six public hospitals across the country.

Also read Prevalance rate of Tuberculosis down, but diabetes cases on the rise

Sanjiv Navangul, MD of Janssen India, the pharma arm of Johnson & Johnson which has manufactured the drug, told the daily, "We are ready with the roll-out of the drug through the government-run control programme, for which 600 patients will be enrolled across the country, over the next six to nine months, after the required tests. Upon the review of clinical data after two years, the access programme will be expanded nationwide."

Though the cost of the drug has not yet been decided, Navangul said that the company will be flexible about pricing as the drug is not about revenue for the company.

However, the report said that Janssen is believed to be offering the drug through a tiered-pricing structure, for example $3,000 in middle-income countries and $900 in low-income countries.

In 2014, over two lakh people died due to Tuberculosis in India, the highest in the world.

As per World Health Organisation (WHO) Global Tuberculosis Report 2015, for the year 2014, deaths due to TB were estimated in India to be 2,20,000 which is higher than any other country.